[Skip to Content]
[Skip to Content Landing]

Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 MonthsThe HPV FOCAL Randomized Clinical Trial

Educational Objective
To learn whether human papillomavirus (HPV) screening is accurate and timely for the detection of cervical cancer.
1 Credit CME
Key Points

Question  Does cervical cancer screening using primary cervical human papillomavirus (HPV) testing compared with cytology result in a lower likelihood of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) at 48 months?

Findings  In this randomized clinical trial that included 19 009 women, screening with primary HPV testing resulted in significantly lower likelihood of CIN3+ at 48 months compared with cytology (2.3/1000 vs 5.5/1000).

Meaning  HPV-based screening resulted in lower likelihood of CIN3+ than cytology after 48 months, but further research is needed to understand long-term clinical outcomes as well as cost-effectiveness.

Abstract

Importance  There is limited information about the relative effectiveness of cervical cancer screening with primary human papillomavirus (HPV) testing alone compared with cytology in North American populations.

Objective  To evaluate histologically confirmed cumulative incident cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) detected up to and including 48 months by primary HPV testing alone (intervention) or liquid-based cytology (control).

Design, Setting, and Participants  Randomized clinical trial conducted in an organized Cervical Cancer Screening Program in Canada. Participants were recruited through 224 collaborating clinicians from January 2008 to May 2012, with follow-up through December 2016. Women aged 25 to 65 years with no history of CIN2+ in the past 5 years, no history of invasive cervical cancer, or no history of hysterectomy; who have not received a Papanicolaou test within the past 12 months; and who were not receiving immunosuppressive therapy were eligible.

Interventions  A total of 19 009 women were randomized to the intervention (n = 9552) and control (n = 9457) groups. Women in the intervention group received HPV testing; those whose results were negative returned at 48 months. Women in the control group received liquid-based cytology (LBC) testing; those whose results were negative returned at 24 months for LBC. Women in the control group who were negative at 24 months returned at 48 months. At 48-month exit, both groups received HPV and LBC co-testing.

Main Outcomes and Measures  The primary outcome was the cumulative incidence of CIN3+ 48 months following randomization. The cumulative incidence of CIN2+ was a secondary outcome.

Results  Among 19 009 women who were randomized (mean age, 45 years [10th-90th percentile, 30-59]), 16 374 (8296 [86.9%] in the intervention group and 8078 [85.4%] in the control group) completed the study. At 48 months, significantly fewer CIN3+ and CIN2+ were detected in the intervention vs control group. The CIN3+ incidence rate was 2.3/1000 (95% CI, 1.5-3.5) in the intervention group and 5.5/1000 (95% CI, 4.2-7.2) in the control group. The CIN3+ risk ratio was 0.42 (95% CI, 0.25-0.69). The CIN2+ incidence rate at 48 months was 5.0/1000 (95% CI, 3.8-6.7) in the intervention group and 10.6/1000 (95% CI, 8.7-12.9) in the control group. The CIN2+ risk ratio was 0.47 (95% CI, 0.34-0.67). Baseline HPV-negative women had a significantly lower cumulative incidence of CIN3+ at 48 months than cytology-negative women (CIN3+ incidence rate, 1.4/1000 [95% CI, 0.8-2.4]; CIN3+ risk ratio, 0.25 [95% CI, 0.13-0.48]).

Conclusions and Relevance  Among women undergoing cervical cancer screening, the use of primary HPV testing compared with cytology testing resulted in a significantly lower likelihood of CIN3+ at 48 months. Further research is needed to understand long-term clinical outcomes as well as cost-effectiveness.

Trial Registration  isrctn.org Identifier: ISRCTN79347302

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Gina Suzanne Ogilvie, MD, FCFP, DrPH, BC Women’s Hospital and Health Centre, 4500 Oak St, Room H203G (Box 42), Vancouver, BC V6H 3N1, Canada (gina.ogilvie@cw.bc.ca).

Accepted for Publication: May 17, 2018.

Correction: This article was corrected on December 4, 2018, to clarify the colposcopy referral rates reported in the Results section.

Author Contributions: Drs Ogilvie and Coldman had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Ogilvie, van Niekerk, Krajden, Smith, Martin, Peacock, Stuart, Franco, Coldman.

Acquisition, analysis, or interpretation of data: Ogilvie, Krajden, Cook, Gondara, Ceballos, Quinlan, Lee, Martin, Gentile, Peacock, Stuart, Franco, Coldman.

Drafting of the manuscript: Ogilvie, van Niekerk, Krajden, Smith, Gondara.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Ogilvie, Gondara, Peacock, Franco, Coldman.

Obtained funding: Ogilvie, van Niekerk, Krajden, Martin, Peacock, Stuart, Franco, Coldman.

Administrative, technical, or material support: Ogilvie, van Niekerk, Krajden, Smith, Ceballos, Quinlan, Lee, Stuart, Coldman.

Supervision: Ogilvie, van Niekerk, Krajden, Quinlan, Peacock, Coldman.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Krajden and Coldman were principal investigators, and Drs Ogilvie, van Niekerk, and Franco and Mr Cook were coinvestigators on investigator-led, industry-funded (Hologic Inc and Roche) adjunct studies to the HPV FOCAL trial, designed to compare the performance of different HPV assays. Funding for the adjunct studies was not applied to the operation of the main HPV FOCAL trial results presented here. Funding for industry-funded studies was issued to the investigator institutions to conduct these adjunct studies and investigators did not personally benefit financially. Dr Krajden also reported receiving grants from Siemens. Ms Smith reported receiving personal fees from Roche Molecular Systems outside the submitted work. Dr Quinlan reported receiving personal fees from Merck, Cook Myosite, and Allergan. Dr Lee reports personal fees from Merck outside the submitted work. Dr Franco reported receiving grants, personal fees, and/or nonfinancial support from Merck, GlaxoSmithKline, and Roche outside the submitted work. No other disclosures were reported.

Funding/Support: This study was funded by grant MCT82072 from the Canadian Institutes of Health Research (CIHR).

Role of the Funder/Sponsor: As part of its review and approval of the funding application, CIHR approved the design, analysis, and conduct of the study. The funder had no role in the collection, management, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References
1.
Arbyn  M, Rebolj  M, De Kok  IM,  et al.  The challenges of organising cervical screening programmes in the 15 old member states of the European Union.  Eur J Cancer. 2009;45(15):2671-2678. doi:10.1016/j.ejca.2009.07.016PubMedGoogle ScholarCrossref
2.
American Society of Clinical Oncology. Cervical cancer: statistics. Cancer.net. http://www.cancer.net/cancer-types/cervical-cancer/statistics. Published July 2017. Accessed April 14, 2018.
3.
Walboomers  JM, Jacobs  MV, Manos  MM,  et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.  J Pathol. 1999;189(1):12-19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-FPubMedGoogle ScholarCrossref
4.
Garland  SM, Kjaer  SK, Muñoz  N,  et al.  Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience.  Clin Infect Dis. 2016;63(4):519-527. doi:10.1093/cid/ciw354PubMedGoogle ScholarCrossref
5.
Jeronimo  J, Castle  PE, Temin  S,  et al.  Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline.  J Glob Oncol. 2016;3(5):635-657. doi:10.1200/JGO.2016.006577PubMedGoogle ScholarCrossref
6.
Murphy  J, Kennedy  EB, Dunn  S,  et al.  HPV testing in primary cervical screening: a systematic review and meta-analysis.  J Obstet Gynaecol Can. 2012;34(5):443-452. doi:10.1016/S1701-2163(16)35241-0PubMedGoogle ScholarCrossref
7.
Ronco  G, Dillner  J, Elfström  KM,  et al; International HPV screening working group.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.  Lancet. 2014;383(9916):524-532. doi:10.1016/S0140-6736(13)62218-7PubMedGoogle ScholarCrossref
8.
Huh  WK, Ault  KA, Chelmow  D,  et al.  Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.  Gynecol Oncol. 2015;136(2):178-182. doi:10.1016/j.ygyno.2014.12.022PubMedGoogle ScholarCrossref
9.
Kulasingam  SL, Havrilesky  L, Ghebre  R, Myers  ER.  Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force: Evidence Syntheses, No. 86s. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
10.
Moyer  VA; US Preventive Services Task Force.  Screening for cervical cancer: US Preventive Services Task Force recommendation statement  [published correction appears in Ann Intern Med. 2013;158(11):852].  Ann Intern Med. 2012;156(12):880-891, W312. doi:10.7326/0003-4819-156-12-201206190-00424PubMedGoogle ScholarCrossref
11.
Coldman  AJ, Gondara  L, Smith  LW,  et al.  Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial.  Br J Cancer. 2016;115(12):1487-1494. doi:10.1038/bjc.2016.368PubMedGoogle ScholarCrossref
12.
Ogilvie  GS, van Niekerk  DJ, Krajden  M,  et al.  A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial).  BMC Cancer. 2010;10:111. doi:10.1186/1471-2407-10-111PubMedGoogle ScholarCrossref
13.
Ogilvie  GS, Krajden  M, van Niekerk  DJ,  et al.  Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial: the HPV FOCAL Study.  Br J Cancer. 2012;107(12):1917-1924. doi:10.1038/bjc.2012.489PubMedGoogle ScholarCrossref
14.
Ogilvie  GS, Krajden  M, van Niekerk  D,  et al.  HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.  Int J Cancer. 2017;140(2):440-448. doi:10.1002/ijc.30454PubMedGoogle ScholarCrossref
15.
Wilson  E.  Probable inference, the law of succession, and statistical inference.  J Am Stat Assoc. 1927;22(158):209-212. doi:10.1080/01621459.1927.10502953Google ScholarCrossref
16.
R Core Team. R: A Language and Environment for Statistical Computing. 2016. http://www.R-project.org/.
17.
Tota  JE, Bentley  J, Blake  J,  et al.  Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm.  Prev Med. 2017;98:5-14. doi:10.1016/j.ypmed.2016.11.029PubMedGoogle ScholarCrossref
18.
Mayrand  MH, Duarte-Franco  E, Rodrigues  I,  et al; Canadian Cervical Cancer Screening Trial Study Group.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.  N Engl J Med. 2007;357(16):1579-1588. doi:10.1056/NEJMoa071430PubMedGoogle ScholarCrossref
19.
Ronco  G, Giorgi-Rossi  P, Carozzi  F,  et al; New Technologies for Cervical Cancer screening (NTCC) Working Group.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.  Lancet Oncol. 2010;11(3):249-257. doi:10.1016/S1470-2045(09)70360-2PubMedGoogle ScholarCrossref
20.
Louvanto  K, Chevarie-Davis  M, Ramanakumar  AV, Franco  EL, Ferenczy  A.  HPV testing with cytology triage for cervical cancer screening in routine practice.  Am J Obstet Gynecol. 2014;210(5):474.e1-474.e7. doi:10.1016/j.ajog.2013.12.033PubMedGoogle ScholarCrossref
21.
Dillner  J, Rebolj  M, Birembaut  P,  et al; Joint European Cohort Study.  Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.  BMJ. 2008;337:a1754. doi:10.1136/bmj.a1754PubMedGoogle ScholarCrossref
22.
Castle  PE, Schiffman  M, Wheeler  CM, Solomon  D.  Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2.  Obstet Gynecol. 2009;113(1):18-25. doi:10.1097/AOG.0b013e31818f5008PubMedGoogle ScholarCrossref
23.
Agramunt  S, Checa  MA, González-Comadrán  M,  et al.  High-grade squamous intraepithelial lesion could be managed conservatively in women up to 25 years: results from a retrospective cohort study.  J Low Genit Tract Dis. 2013;17(4):459-462. doi:10.1097/LGT.0b013e3182838b7cPubMedGoogle ScholarCrossref
24.
Loopik  DL, Doucette  S, Bekkers  RL, Bentley  JR.  Regression and progression predictors of CIN2 in women younger than 25 years.  J Low Genit Tract Dis. 2016;20(3):213-217. doi:10.1097/LGT.0000000000000215PubMedGoogle ScholarCrossref
25.
Bulkmans  NW, Berkhof  J, Rozendaal  L,  et al.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.  Lancet. 2007;370(9601):1764-1772. doi:10.1016/S0140-6736(07)61450-0PubMedGoogle ScholarCrossref
26.
Dijkstra  MG, van Zummeren  M, Rozendaal  L,  et al.  Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.  BMJ. 2016;355:i4924. doi:10.1136/bmj.i4924PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close